Michael joined USP in 2016 as Vice President to lead the creation of USP’s Quality Institute. In 2017, his role expanded to include USP’s Research & Innovation efforts. He has been a member of USP’s executive team and Senior Vice President of Digital & Innovation since 2020.
In his current role, Michael drives the organization's digital transformation, working to leverage new technologies, data, and informatics to improve the quality and availability of medicines. He leads the exploration of emerging innovations and technologies, as well as the development of new digital products based on USP’s vast data and scientific content to transform the way stakeholders assess the resilience of medicine supply chains, ensure the quality of medicines, and integrate USP standards into their increasingly automated and digital workflows.
Before joining USP, Michael held various leadership roles, including Deputy Vice President at PhRMA, Associate Principal at McKinsey & Company, and bioinformatician with the team that sequenced Human Chromosome XIV as part of the Human Genome Project.
Career Highlights:
- PhRMA: Deputy Vice President, Science and Regulatory Advocacy
- McKinsey & Company: Associate Principal, Pharmaceutical and Medical Products practice
- Genomining: Lead bioinformatics developer
- Genoscope, the French National Genome Center: Bioinformatician, Human Genome Project
Education:
- Cornell Johnson Graduate School of Management, M.B.A.
- Concordia University, B.S. and M.Sc., Biology
Professional Achievements:
- Defining, establishing, and initially leading the USP Quality Institute
- Influencing the content of the PDUFA V Goals Letter and the 21st Century Cures Act by leading the definition of the Pharmaceutical Industry advocacy position on the use of Real World Evidence in Regulatory decision making
- Participating in the Human Genome Project by automating the genomic sequence assembly, quality assessment, and lab operations of Human Chromosome XIV
